ArticleThe Journal of clinical investigation1999
Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells.
Article in The Journal of clinical investigation, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 142 citations in OpenAlex.
- Sexual Dimorphism in Sex Hormone Metabolism in Human Skeletal Muscle Cells in Response to Different Testosterone Exposure.Biology · 2024Article
- The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy.Frontiers in oncology · 2023Review
- Estradiol and zinc-doped nano hydroxyapatite as therapeutic agents in the prevention of osteoporosis; oxidative stress status, inflammation, bone turnover, bone mineral density, and histological alterations in ovariectomized rats.Frontiers in physiology · 2022Article
- Regulatory roles of miRNAs 16, 133a, and 223 on osteoclastic bone destruction caused by breast cancer metastasis.International journal of oncology · 2021Article
- Analyses of the association between breast cancer and osteoporosis/fracture history: a cross-sectional study using KoGES HEXA data.Archives of osteoporosis · 2021Article
- Estrogen and bones after menopause: a reappraisal of data and future perspectives.Hormones (Athens, Greece) · 2021Review
- Molecular mechanisms and clinical management of cancer bone metastasis.Bone research · 2020Review
- Wnt5a mediates the effects of Bushen Huoxue decoction on the migration of bone marrow mesenchymal stem cells in vitro.Chinese medicine · 2018Article
- Estrogens and Androgens in Skeletal Physiology and Pathophysiology.Physiological reviews · 2017Review
- Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates.Pharmaceutics · 2016Review
- Prostate cancer and osteoporosis.Current osteoporosis reports · 2013Article
- Direct transcriptional targets of sex steroid hormones in bone.Journal of cellular biochemistry · 2011Review
- Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2).International journal of clinical and experimental pathology · 2009Article
- Osteoimmunology: interactions of the bone and immune system.Endocrine reviews · 2008Review
- Ligand-modified aminobisphosphonate for linking proteins to hydroxyapatite and bone surface.Bioconjugate chemistry · 2008Article
- Postmenopausal tibolone therapy: biologic principles and applied clinical practice.MedGenMed : Medscape general medicine · 2007Review
- Review
- Tumor necrosis factor alpha (TNF-α) and estrogen hormone in osteoarthritic female patients.Indian journal of clinical biochemistry : IJCB · 2006Article
- Absence of platelet-activating factor receptor protects mice from osteoporosis following ovariectomy.The Journal of clinical investigation · 2004Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Declining estrogen levels during the first postmenopausal decade lead to rapid bone loss and increased fracture risk that can be reversed by estrogen replacement therapy. The bone-protective effects of estrogen may involve suppression of inflammatory cytokines that promote osteoclastogenesis and bone resorption, such as IL-1, TNF-alpha, and IL-6. We investigated whether estrogen modulates IL-1 actions on human osteoclasts (OCs) and other bone cell types. Isolated human OCs and primary bone marrow-derived OC-like cells expressed both the signaling (IL-1RI) and decoy (IL-1RII) IL-1 receptors, whereas only IL-1RI was detected in osteoblasts. IL-1RII/IL-1RI mRNA ratios and release of soluble IL-1RII (sIL-1RII) were lower in OC-like cells derived from women in the late postmenopausal period compared with younger women, but were unrelated to male donor age, suggesting that estrogen might play a role in regulating IL-1 receptor levels in vivo. Estrogen directly reduced in vitro OC-like cell IL-1RI mRNA levels while increasing IL-1RII mRNA levels and sIL-1RII release. These estrogenic events were associated with inhibited IL-1-mediated cytokine (IL-8) mRNA induction and cell survival, i.e., increased apoptosis. In contrast, estrogen did not alter IL-1R levels or IL-1 responsiveness in primary human osteoblasts or bone marrow stromal cells. We conclude that one novel mechanism by which estrogen exerts bone-protective effects may include a selective modulation of IL-1R isoform levels in OC or OC-like cells, thereby reducing their IL-1 responsiveness and cell survival. Conversely, this restraint on IL-1 actions may be lost as estrogen levels decline in aging women, contributing to an enhanced OC-mediated postmenopausal bone loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.